<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC7045215/results/search/drug/results.xml">
  <result pre="pmcid: 7045215bmjopen-2019-032112 doi: 10.1136/bmjopen-2019-032112 : Neurology: Protocol: 15061713 Antiviral therapy:" exact="Valacyclovir" post="Treatment of Alzheimer’s Disease (VALAD) Trial: protocol for a"/>
  <result pre="antiviral medication treatment reduces this risk. The generic antiviral drug" exact="valacyclovir" post="was superior to placebo in improving memory in a"/>
  <result pre="be compared with placebo (lactose pills) in 130 patients (65" exact="valacyclovir" post="and 65 placebo) in a randomised, double-blind, 78-week phase"/>
  <result pre="tau accumulation, respectively. In the lumbar puncture subsample, cerebrospinal fluid" exact="acyclovir" post="will be assayed to assess central nervous system valacyclovir"/>
  <result pre="fluid acyclovir will be assayed to assess central nervous system" exact="valacyclovir" post="penetration. Ethics and dissemination The trial is being overseen"/>
  <result pre="and conferences. Trial registration number ClinicalTrials.gov identifier (NCT03282916) Pre-results. virus" exact="valacyclovir" post="Alzheimer’s disease mild cognitive impairment biomarkers Funding http://dx.doi.org/10.13039/100000049National Institute"/>
  <result pre="by HSV2.11 In a cell-culture model, the antiviral medications acyclovir," exact="penciclovir" post="and foscarnet reduced HSV1 particles and Aβ and phosphorylated"/>
  <result pre="disruption with ageing supports viral entry. Clinically, antiviral treatment with" exact="acyclovir" post="or valacyclovir is effective in reducing mortality and severity"/>
  <result pre="ageing supports viral entry. Clinically, antiviral treatment with acyclovir or" exact="valacyclovir" post="is effective in reducing mortality and severity of cognitive"/>
  <result pre="the effects of HSV in the brain. Antiviral treatment with" exact="valacyclovir" post="Valacyclovir, a widely used generic antiviral medication, is approved"/>
  <result pre="HSV2, herpes zoster and chickenpox.30 No other antiviral drug, including" exact="acyclovir" post="(intravenous), famciclovir and ganciclovir, is superior to valacyclovir in"/>
  <result pre="zoster and chickenpox.30 No other antiviral drug, including acyclovir (intravenous)," exact="famciclovir" post="and ganciclovir, is superior to valacyclovir in the treatment"/>
  <result pre="drug, including acyclovir (intravenous), famciclovir and ganciclovir, is superior to" exact="valacyclovir" post="in the treatment of HSV1 and HSV2 infections. Acting"/>
  <result pre="of HSV1 and HSV2 infections. Acting as an oral pro-drug," exact="valacyclovir" post="is converted in vivo to acyclovir, which is then"/>
  <result pre="which is then converted by viral thymidine kinase into its" exact="acyclovir" post="monophosphate (acyclo-GMP) and acyclovir triphosphate (acyclo-GTP) forms. Acyclo-GTP is"/>
  <result pre="by viral thymidine kinase into its acyclovir monophosphate (acyclo-GMP) and" exact="acyclovir" post="triphosphate (acyclo-GTP) forms. Acyclo-GTP is a potent inhibitor of"/>
  <result pre="also incorporates into viral DNA, leading to chain termination. Therefore," exact="valacyclovir" post="leads to the death of infected cells without affecting"/>
  <result pre="of non-infected cells; hence, its side effect profile is benign." exact="Valacyclovir" post="has been tested in multiple sclerosis (MS) with equivocal"/>
  <result pre="trial in 24 patients with schizophrenia with positive HSV1 titres," exact="valacyclovir" post="3 g/day was superior to placebo with effect sizes of"/>
  <result pre="cognitive deficits in schizophrenia, specifically in individuals with HSV seropositivity." exact="Valacyclovir" post="also improves cognition in patients with HSE, but controlled"/>
  <result pre="cognition in patients with HSE, but controlled trials are lacking.16" exact="Valacyclovir" post="has a generally benign safety profile with minimally higher"/>
  <result pre="the post-marketing phase, initial double-blind followed by intermittent and continuous" exact="valacyclovir" post="treatment for up to 7 years showed no major"/>
  <result pre="failure who are taking valacyclovir.36 The recommended oral dose of" exact="valacyclovir" post="for peripheral acute HSV infections is 1–3 g daily, and"/>
  <result pre="daily. In the schizophrenia pilot trial that showed superiority for" exact="valacyclovir" post="compared with placebo, the efficacious dose was 3 g daily.33"/>
  <result pre="choice of a flexible dose range of 2–4 g daily for" exact="Valacyclovir" post="Treatment of Alzheimer’s Disease (VALAD). The dose range of"/>
  <result pre="penetration with a largely linear relationship between oral dose of" exact="valacyclovir" post="and cerebrospinal fluid (CSF) acyclovir levels. In MS, sustained"/>
  <result pre="relationship between oral dose of valacyclovir and cerebrospinal fluid (CSF)" exact="acyclovir" post="levels. In MS, sustained CSF acyclovir levels persist for"/>
  <result pre="and cerebrospinal fluid (CSF) acyclovir levels. In MS, sustained CSF" exact="acyclovir" post="levels persist for at least 6 months with continuing"/>
  <result pre="acyclovir levels persist for at least 6 months with continuing" exact="valacyclovir" post="treatment.35 Based on the literature, CSF acyclovir levels are"/>
  <result pre="months with continuing valacyclovir treatment.35 Based on the literature, CSF" exact="acyclovir" post="levels are likely to be in the 3–6 µM range"/>
  <result pre="are likely to be in the 3–6 µM range with oral" exact="valacyclovir" post="doses of 2–4 g daily.37 This study will evaluate whether"/>
  <result pre="2–4 g daily.37 This study will evaluate whether antiviral treatment with" exact="valacyclovir" post="can improve cognition and function in patients with HSV"/>
  <result pre="randomised, double-blind, placebo-controlled, 18-month treatment trial of 130 patients (65" exact="valacyclovir" post="and 65 placebo) with mild AD and antibodies to"/>
  <result pre="We are interested in the effects of the antiviral drug" exact="valacyclovir" post="on cognition and function as clinical outcomes, and on"/>
  <result pre="basic science literature on the effects of antiviral drugs like" exact="valacyclovir" post="on amyloid and tau and other measures that are"/>
  <result pre="the patient will be eligible. Use of cholinesterase inhibitors and" exact="memantine" post="is permitted. Doses of these medications need to be"/>
  <result pre="(other than benzodiazepines prescribed at a dose equivalent of 2 mg" exact="lorazepam" post="daily or higher) and other medications prescribed for medical"/>
  <result pre="based on clinical assessment. Current or recent (past 6 months)" exact="alcohol" post="or substance use disorder (DSM-5 criteria). Current diagnosis of"/>
  <result pre="thrombocytopenic purpura/haemolytic uremic syndrome will be excluded (specific exclusion for" exact="valacyclovir" post="as per FDA package insert). Use of benzodiapezines in"/>
  <result pre="valacyclovir as per FDA package insert). Use of benzodiapezines in" exact="lorazepam" post="equivalent doses equal to or greater than 2 mg daily."/>
  <result pre="MRI but without clinical deficits due to stroke are included." exact="Valacyclovir" post="is excreted through the kidneys. A study of over"/>
  <result pre="through the kidneys. A study of over 76 000 patients taking" exact="acyclovir" post="or valacyclovir showed no increase in kidney disease.39 Valacyclovir"/>
  <result pre="kidneys. A study of over 76 000 patients taking acyclovir or" exact="valacyclovir" post="showed no increase in kidney disease.39 Valacyclovir also has"/>
  <result pre="taking acyclovir or valacyclovir showed no increase in kidney disease.39" exact="Valacyclovir" post="also has no significant interactions in patients on diuretics,40"/>
  <result pre="&amp;lt;60.41 If a patient is receiving a cholinesterase inhibitor and/or" exact="memantine" post="to treat AD, the dose needs to be stable"/>
  <result pre="to study entry. Psychotropic and other medications will be permitted;" exact="valacyclovir" post="has no significant drug–drug or drug–food interactions.30 All medication"/>
  <result pre="is 5 years. Randomisation The NYSPI pharmacy will make up" exact="valacyclovir" post="500 mg tablets and placebo into identical-looking capsules. The randomisation"/>
  <result pre="are created for patients from Columbia and NYU. Treatment regimen" exact="Valacyclovir" post="or placebo will be started at 2 g daily (1 g"/>
  <result pre="in swallowing the large 1 g pill. Patients who cannot tolerate" exact="valacyclovir" post="2 g per day (or matching placebo) will discontinue treatment"/>
  <result pre="kidney functions, liver functions and other tests (Sequential Multiple Analysis—Computer)," exact="folate" post="and vitamin B12 levels, thyroid functions and serum viral"/>
  <result pre="the maximum tolerated dose. Table 1 Study procedures for the" exact="Valacyclovir" post="Treatment of Alzheimer’s Disease Trial Procedure Screening 0 weeks"/>
  <result pre="differential X       X     X Plasma" exact="acyclovir" post="levels         X     X"/>
  <result pre="levels         X     X *CSF" exact="acyclovir" post="levels         X     X"/>
  <result pre="laboratory at the University of Alabama will examine CSF for" exact="acyclovir" post="levels and plasma acyclovir levels. We also obtain CSF"/>
  <result pre="of Alabama will examine CSF for acyclovir levels and plasma" exact="acyclovir" post="levels. We also obtain CSF Aβ42 and tau/phospho-tau protein"/>
  <result pre="On the ADAS-Cog11 (cognitive measure; 0–78 weeks), patients treated with" exact="valacyclovir" post="will show smaller decline than patients treated with placebo."/>
  <result pre="On the ADCS-ADL (function measure; 0–78 weeks), patients treated with" exact="valacyclovir" post="will show smaller decline than patients treated with placebo."/>
  <result pre="3. On PET scans (18F-Florbetapir, 0–78 weeks), patients treated with" exact="valacyclovir" post="will show less amyloid accumulation than patients treated with"/>
  <result pre="On tau PET scans (18F-MK-6240, 0–78 weeks), patients treated with" exact="valacyclovir" post="will show less tau accumulation on the sum of"/>
  <result pre="cortical thinning and whole brain cortical thinning,52 53 and CSF" exact="acyclovir" post="levels to examine plasma/CSF acyclovir correlations. CSF studies will"/>
  <result pre="cortical thinning,52 53 and CSF acyclovir levels to examine plasma/CSF" exact="acyclovir" post="correlations. CSF studies will be optional and approximately one-third"/>
  <result pre="that gets CSF studies, we will obtain plasma and CSF" exact="acyclovir" post="levels and examine plasma/CSF ratios; we will also obtain"/>
  <result pre="and randomisation: The sample (n=130) will be randomised 1:1 to" exact="valacyclovir" post="or placebo with the randomisation sequences balanced in blocks"/>
  <result pre="there is any evidence of randomisation imbalance. Cholinesterase inhibitors and/or" exact="memantine" post="that are permitted during the trial may be related"/>
  <result pre="control for their presence or absence. Hypothesis 3. Patients on" exact="valacyclovir" post="will demonstrate less increase (less accumulation) in 18F-Florbetapir uptake"/>
  <result pre="corresponds to a 3-point difference on ADAS-Cog11 scores between the" exact="valacyclovir" post="and placebo groups by week 78. Assuming a SD"/>
  <result pre="phase II study, if there is a significant effect favouring" exact="valacyclovir" post="over placebo on one or both of the efficacy"/>
  <result pre="10.1212/WNL.58.1.3111781402 32FriedmanJE, ZabriskieJB, PlankC, et al.A randomized clinical trial of" exact="valacyclovir" post="in multiple sclerosis. Mult Scler2005;11:286–95. 10.1191/1352458505ms1185oa15957509 33PrasadKM, EackSM, KeshavanMS,"/>
  <result pre="44RogersSL, FarlowMR, DoodyRS, et al.A 24-week, double-blind, placebo-controlled trial of" exact="donepezil" post="in patients with Alzheimer's disease. Neurology1998;50:136–45. 10.1212/WNL.50.1.1369443470 45LinM, GongP,"/>
 </snippets>
</snippetsTree>
